Clinical trials
Phase 2 trials in Belarus
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
37 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2007 | 1 |
| 2009 | 1 |
| 2011 | 2 |
| 2013 | 2 |
| 2014 | 4 |
| 2015 | 3 |
| 2017 | 3 |
| 2018 | 4 |
| 2019 | 6 |
| 2020 | 4 |
| 2021 | 4 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 24 |
| Terminated | 5 |
| Unknown status | 5 |
| Active, not recruiting | 2 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Biocad | 4 |
| Abivax S.A. | 2 |
| Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | 2 |
| Actelion | 1 |
| Applied Molecular Transport | 1 |
| Ardana Bioscience Ltd | 1 |
| Aridis Pharmaceuticals, Inc. | 1 |
| Ascendis Pharma A/S | 1 |
| Astellas Pharma Europe B.V. | 1 |
| Aurinia Pharmaceuticals Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Colitis, Ulcerative | 8 |
| Dwarfism, Pituitary | 3 |
| Inflammatory Bowel Diseases | 2 |
| Adenocarcinoma of Lung | 1 |
| Anemia | 1 |
| Atrial Fibrillation | 1 |
| Breast Neoplasms | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Carcinoma, Squamous Cell | 1 |
| Endometrial Neoplasms | 1 |
Trials
Showing 51 to 37 of 37. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.